MPR3d
FDA to Review Depemokimab for Asthma With Eosinophilic Phenotype, CRSwNP
The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...
Clinical Trials Arena on MSN10d
GSK reports positive outcomes from two Phase III trials of treatment for CRSwNP
Secondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.
EconoTimes10d
FDA Reviews GSK’s Depemokimab for Asthma and CRSwNP Treatment
The U.S. Food and Drug Administration (FDA) has accepted GlaxoSmithKlines (NYSE:GSK) biologics license application for ...
PharmExec10d
FDA Accepts Biologics License Application for GSK’s Depemokimab for Asthma with Type 2 Inflammation and CRSwNP
In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...
Pulmonology Advisor3d
Silent Rhinovirus Infection Prevalent in Nasal Tissues
Silent rhinovirus (RV) infection is prevalent in nasal tissues and is associated with distinct immune responses in those with and without chronic rhinosinusitis with nasal polyps (CRSwNP). These were ...
Hosted on MSN1mon
Depemokimab reviewed for asthma and CRSwNP in Asia
a new biologic treatment for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP). If approved, depemokimab would be the first biologic of its kind to offer a six ...
pharmaphorum4d
GSK asthma hope depemokimab works in second indication
GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...
Pharmabiz10d
US FDA accepts for review GSK’s BLA for depemokimab for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps
US FDA accepts for review GSK’s BLA for depemokimab for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps: London, UK Tuesday, March 4, 2025, 09:0 ...
Investing.com Australia10d
US FDA accepts GSK’s application for Depemokimab review
Investing.com -- The US Food and Drug Administration has accepted GlaxoSmithKline (NYSE: GSK )’s biologics license ...
Pharmabiz1mon
GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP
Type 2 inflammation is also present in up to 80% of people with CRSwNP and is associated with more severe disease and symptoms. Asthma is a major health burden in China affecting an estimated 46 ...
clinicaladvisor.com4d
FDA to Review Depemokimab for Asthma With Eosinophilic Phenotype, CRSwNP
for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP). Depemokimab is an ultra-long acting biologic with high binding affinity for interleukin-5.
Yahoo Finance11d
GSK reports positive outcomes from two Phase III trials of treatment for CRSwNP
Data from the ANCHOR and SWIFT trials are being used to support regulatory filings for depemokimab in various nations for the treatment of asthma with type 2 inflammation and CRSwNP. The antibody ...